Latest Email from Leslie (11 Feb 2020 @ 9am), page-5

For the record - Attached Below

Abstract

Background

Peritoneal carcinomatosis (PC) from pancreatic ductal adenocarcinoma (PDAC) is fatal. Our preclinical study presents an effective treatment against PDAC PC employing a novel oncolytic viral agent, CF33-hNIS-antiPDL1.

Study Design

CF33-hNIS-antiPDL1 is a genetically engineered chimeric orthopoxvirus, CF33, armed with the human Sodium Iodide Symporter (hNIS) and anti-PD-L1 antibody (anti-PD-L1). The in vitro cytotoxic ability of this virus against five PDAC cell lines was tested at various doses (multiplicity of infection (MOI) = 0.01, 0.1, 1, 10). Production and blockade function of virus-encoded anti-PD-L1 antibody were verified using immunoblot, immunoprecipitation, and PD-1/PD-L1 bioassay. In vivo mouse models of PC, with or without subcutaneous (SC) tumors created by injecting AsPC-1-ffluc cells into nude mice, were treated with PBS or a single dose (1x10⁵ plaque-forming units) of either intraperitoneal (IP) or intravenous (IV) injections of CF33-hNIS-antiPDL1. Mice with PC tumors were treated on days 0, 2, or 14 following tumor implantation.

Results

CF33-hNIS-antiPDL1 killed PDAC cells in a dose-dependent manner achieving >90% cell killing by day 8. Cells infected with CF33-hNIS-antiPDL1 produced bioactive anti-PD-L1 antibody which blocked PD-1/PD-L1 interaction. In vivo, single dose of virus reduced tumor burden and prolonged survival of treated mice. It was observed that IP administration of CF33-hNIS-antiPDL1 was more effective than IV administration.

Conclusion

CF33-hNIS-antiPDL1 virus is effective in infecting and killing human PDACs and producing functional anti-PD-L1 antibody. IP delivery of CF33-hNIS-antiPDL1 effectively reduces peritoneal tumor burden and improves survival after only one dose and is superior to IV delivery.